Zylol 25 XR Tablet contains Metoprolol Succinate 25 mg, a cardioselective beta-1 adrenergic receptor blocker used primarily in the management of hypertension, angina pectoris, and heart failure. By selectively inhibiting beta-1 receptors in the heart, Metoprolol reduces heart rate, myocardial contractility, and cardiac output, thereby decreasing oxygen demand and lowering blood pressure. The extended-release formulation ensures a consistent plasma concentration, allowing once-daily dosing and improved patient compliance. Zylol 25 XR is indicated for the treatment of essential hypertension, stable angina, and for reducing cardiovascular mortality following myocardial infarction. It is also employed in managing chronic heart failure as part of a comprehensive therapeutic regimen. The tablet should be administered orally, preferably with or immediately after meals to enhance absorption. Dosage adjustments may be necessary in patients with hepatic impairment or bradycardia. Common adverse effects include fatigue, dizziness, and gastrointestinal disturbances, while serious side effects may involve bradyarrhythmias, hypotension, or bronchospasm, particularly in patients with reactive airway disease. Caution is advised when discontinuing therapy to avoid exacerbation of angina or precipitating myocardial infarction. Zylol 25 XR should be used under medical supervision with regular monitoring of heart rate, blood pressure, and clinical response.